Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr;111(4):899-900.
doi: 10.1111/apa.16212. Epub 2022 Jan 4.

EBNEO Commentary: Effect of systemic hydrocortisone initiated 7-14 days after birth in ventilated preterm infants on mortality and neurodevelopment at 2 years' corrected age

Gillian W Foo  1 , Brett J Manley  1   2   3 , Peter G Davis  1   2   3
Affiliations
Comment

EBNEO Commentary: Effect of systemic hydrocortisone initiated 7-14 days after birth in ventilated preterm infants on mortality and neurodevelopment at 2 years' corrected age

Gillian W Foo et al. Acta Paediatr. 2022 Apr.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;10(10):CD001146.
    1. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;11(11):CD001145.
    1. Baud O, Maury L, Lebail F, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 2016;387(10030):1827-1836. Epub 2016 Feb 23.
    1. Baud O, Trousson C, Biran V, et al. Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth. Arch Dis Child Fetal Neonatal Ed. 2019;104:F30-F35.
    1. Owen LS, Cheong JL, Davis PG. Bronchopulmonary dysplasia as a trial endpoint: time for re-evaluation? Lancet Child Adolesc Health. 2019;3(12):842-844.

LinkOut - more resources